Novo’s H1 Exceeds Estimates On GLP-1, Obesity Sales Performance

Full-Year Guidance Raised Again With Wegovy Factored In

The company’s semaglutide franchise pushed net sales for the first half of 2021 up 5% year over year at DKK66.8bn ($10.6bn), helped by double- and triple-digit growth for Ozempic and Rybelsus.

Novo has received positive early feedback on Wegovy from prescribers and patients in the US • Source: Alamy

The importance of its semaglutide franchise – including newly approved obesity drug Wegovy – to Novo Nordisk A/S’s ongoing sales growth was apparent as the company laid out its financial performance for the first half of 2021; the various iterations of the drug comprise nearly a quarter of the firm’s sales, excluding Wegovy, which the firm reported is off to a strong launch.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

18 Apr 2025

• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

16 Apr 2025

• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

14 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.